Follicular Lymphoma

GSK Starts Preparations for Regulatory Filings as RSV Vaccine Clears Phase III Test in Adults GSK plans to initiate preparation for regulatory submissions for its respiratory syncytial virus (RSV) vaccine after the vaccine performed well in the much-anticipated AReSVi 006 trial in individuals aged 60 and above.&...

Bristol-Myers Squibb’s Opdivo Gets FDA Approval for Esophageal Cancer The FDA has approved two combination drug regimens based on Bristol-Myers Squibb’s PD-1 inhibitor Opdivo for previously untreated advanced Esophageal Cancer, encroaching on the territory belonging to Merck & Co’s rival Keytruda. The latest...

AstraZeneca’s Farxiga Meets Primary Endpoints in Phase 3 Heart Failure Trial Farxiga, an SGLT2 inhibitor from AstraZeneca, has shown positive results in a phase 3 Heart Failure trial, putting it back in contention with Jardiance from Boehringer Ingelheim and Eli Lilly. The DELIVER trial's top-line results demons...

Merck’s Chronic Cough Med Gefapixant Receives A Red Flag From the FDA, Requests For More Data On 24th January 2022, Merck & Co. announced FDA rejection for its New Drug Application (NDA) of Gefapixant (experimental drug) for unexplained or chronic cough. FDA asked for additional information on the drug, rela...

The innovation in the oncology drug pipeline has resulted in a record number of FDA and EU approvals in recent years, as investigators and sponsors seek new and targeted treatments for individuals diagnosed with different types of cancers each year. In 2022, regulators will continue to evaluate new oncology therapi...

ASH 2021,which ended on December 14, 2021, was a premier event in malignant and non-malignant hematology. Like every year, key pharma players took center stage and shared new data regarding the development of their primary candidates in cancer and blood disorders, showcasing the impact of ongoing research. DelveIns...

Follicular Lymphoma is the second most widespread non-Hodgkin lymphoma subtype, accounting for roughly 20% of all NHL cases. It is a slow-growing (low-grade) NHL that develops from B cells. It is called follicular lymphoma because the abnormal B cells usually develop in clumps called ‘follicles’ inside lymph nodes....

Follicular lymphoma, a sub-type of indolent B cell non-Hodgkin lymphoma (NHL), accounts for approximately 20% of the total NHL cases. It is the most frequently diagnosed indolent lymphoma. On average, each year, 15,000 new Follicular lymphoma cases are diagnosed in the US alone. DelveInsight estimated that in 2020 ...